6533b7d3fe1ef96bd1260297

RESEARCH PRODUCT

The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome

Vincent J. CareyMichel P. HermansAntonio Hernández MijaresJean-charles FruchartJesús Millán Núñez-cortésJuan Pedro-botet MontoyaXavier Pintó SalasFrank M. Sacks

subject

MaleRiskmedicine.medical_specialtyAcute coronary syndromeInternational CooperationRisk AssessmentMedical RecordsMeta-Analysis as TopicRecurrenceInternal medicinemedicineHumansAcute Coronary SyndromeAgedDyslipidemiasRetrospective StudiesAged 80 and overHypertriglyceridemiamedicine.diagnostic_testbusiness.industryPatient SelectionStandard treatmentCholesterol HDLCase-control studyRetrospective cohort studyCholesterol LDLMiddle AgedAtherosclerosismedicine.diseaseLipidsSurgeryResidual riskCardiovascular DiseasesCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profileRisk assessmentbusinessDyslipidemia

description

The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.

yearjournalcountryeditionlanguage
2010-07-08Endocrinología y Nutrición (English Edition)
https://doi.org/10.1016/s2173-5093(11)70035-6